IL17A and breast cancer: To identify equivalent clusters across BC and blood γδ-T datasets, we used scID (Boufea et al, 2020) which revealed that BC γδ-T.1 cluster was equivalent to blood c.γδ3 cluster (and consistent with both being marked by CD16 and positive for IFNγ) and BC γδ-T.3 cluster was equivalent to blood c.γδ5 cluster (and consistent with both being marked by CCR6 and positive for IL17A) (Figs 4B and C, 1E, and 3E).